Clinical trial
The Relationship of RAGE Gene Polymorphism (rs1800625) With Type I Diabetes Mellitus Incidence, Severity, and Inflammatory Reactions in Egyptian Patients on MicroRNAs (MiRNA-34, MiRNA-146): A Case-control Study
Name
IDE00296
Description
Type I Diabetes Mellitus (TIDM) is a chronic metabolic disorder caused by the immune-mediated T-cell and macrophages that typically affects insulin-producing β-cells of Langerhans leading to cell destruction and absolute insulin deficiency. This study aimed to investigate the correlation of RAGE gene polymorphism rs1800625 with the incidence of type I diabetes mellitus in the Egyptian patients with the activity and the severity of the disease and to assess their association with inflammatory reactions in TIDM patients (IL-6, TNF-α). Also, this study investigated the relation between MiRNA-34, MiRNA-146, to TID severity and activity
Trial arms
Trial start
2023-01-01
Estimated PCD
2023-05-10
Trial end
2023-05-10
Status
Completed
Treatment
Detection of RAGE gene polymorphism (rs1800625)
Detection of RAGE gene polymorphism (rs1800625) By Molecular analysis (real time PCR)
Arms:
Control, Type I Diabetes Mellitus
Size
354
Primary endpoint
correlation of RAGE gene polymorphism rs1800625 with the incidence of type I diabetes
4 months
Eligibility criteria
Inclusion Criteria:
* \<18 Years
Exclusion Criteria:
* \> 65
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'SCREENING', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 354, 'type': 'ACTUAL'}}
Updated at
2023-08-23
1 organization
1 product
1 indication
Organization
Future University in EgyptIndication
Type 1 diabetes